BioCardia (BCDA) Expected to Announce Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect BioCardia to post earnings of ($0.87) per share and revenue of $0.02 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

BioCardia Stock Down 2.3 %

Shares of NASDAQ:BCDA opened at $2.60 on Tuesday. BioCardia has a fifty-two week low of $1.63 and a fifty-two week high of $6.41. The firm’s 50 day moving average price is $2.42 and its 200 day moving average price is $2.41. The stock has a market cap of $11.92 million, a price-to-earnings ratio of -0.62 and a beta of 1.28.

Analyst Upgrades and Downgrades

Several analysts recently commented on BCDA shares. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Wednesday, December 18th. Alliance Global Partners upgraded shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 30th.

Insider Activity

In related news, Director Simon H. Stertzer acquired 22,753 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were acquired at an average cost of $2.30 per share, for a total transaction of $52,331.90. Following the acquisition, the director now directly owns 40,602 shares in the company, valued at approximately $93,384.60. The trade was a 127.47 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders acquired a total of 25,353 shares of company stock valued at $58,525 over the last quarter. Company insiders own 20.00% of the company’s stock.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.